Compare POWW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWW | ALXO |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | 81 | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.8M | 240.8M |
| IPO Year | N/A | 2020 |
| Metric | POWW | ALXO |
|---|---|---|
| Price | $2.14 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.40 | ★ $3.50 |
| AVG Volume (30 Days) | 485.5K | ★ 1.0M |
| Earning Date | 02-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.56 | N/A |
| Revenue Next Year | $0.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $0.41 |
| 52 Week High | $2.23 | $2.66 |
| Indicator | POWW | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 43.85 |
| Support Level | $1.99 | $1.41 |
| Resistance Level | $2.20 | $1.90 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 67.92 | 38.89 |
Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.